Large Molecule / Generic

Nexus Pharma to build sterile injectable facility in Wisconsin

Jul 12, 2019

Illinois-based Nexus Pharmaceuticals is planning a $250-million project in Wisconsin in order to build and equip a 100,000-square-foot, three-story sterile drug manufacturing facility.

Nexus is a woman-owned, privately-held pharma company that produces specialty and generic injectable drugs. Previously relying on contract manufacturers, this is the company's first manufacturing facility. 

The project will require the company to more than double it's current workforce of 58 employees. After the facility and equipment are approved by regulatory agencies, commercial production is expected to begin in 2022.

Read the press release 

Learn more about Nexus Pharma

Don't miss your Daily Dose. Sign up to get news like this delivered right to your inbox.